Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2011-03-01
2011-03-01
Zucker, Paul A (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C562S469000
Reexamination Certificate
active
07897643
ABSTRACT:
The present disclosure relates to compounds having the general Formula (I) with the definitions of R1, R2, R3, and R4as provided herein, and/or salts thereof. The disclosure also relates to the use of such compounds for the treatment of Alzheimer's disease, and for the modulation of γ-secretase activity.
REFERENCES:
patent: 5877399 (1999-03-01), Hsiao et al.
patent: 1650183 (2006-04-01), None
patent: WO 01/78721 (2001-10-01), None
patent: WO 03/008635 (2003-01-01), None
patent: WO 2006/004555 (2006-01-01), None
patent: WO 2006005554 (2006-05-01), None
Citron, M., et al. “Mutant Presenilins of Alzheimer's Disease Increase Production of 42-Residue Amyloid β-Protein in Both Transfected Cells and Transgenic Mice”, Nature Medicine, vol. 3, No. 1, 1997, pp. 67-72.
During, M., et al. “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization”, (Abstract) Annals of Neurology, vol. 25, Issue 4, pp. 351-356.
Eriksen, J., et al. NSAIDs and Enantiomers of Flurbiprofen Target γ-secretase and Lower Aβ42 In Vivo, Journal of Clinical Investigation, vol. 112, No. 3, (2003) pp. 440-449.
Ida, N., et al. “Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay”, Journal of Biological Chemistry, vol. 271k No. 37, (19960, pp. 22908-22914.
Irizarry, M., et al., “APPSW Transgenic Mice Developed Age-Related A Deposits and Neuropil Abnormalities”, Journal of Neuropathology & Experimental Neurology 56(9): 965-973 (1997) Abstract.
Kawabayashi, T., et al. “Age-Dependent Changes in Brain, CSF, and Plasma Amyloid βProtein in the Tg2576 Transgenic Mouse model of Alzheimer's Disease”, Journal of Neuroscience, 21(2): pp. 372-381 (2001).
Langer, R., “New Methods of Drug Delivery”, Science, vol. 249, Issue 4976, pp. 1527-1533 (1990) Abstract.
Larner, A. Secretases as Therapeutic Targets in Alzheimer's Disease: Patents 200-2004, Expert Opinion ther. Patents (2004), 14(10), pp. 1403-1420.
Levy, R., et al. “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate”, Science, vol. 228, Issue 4969, pp. 190-192 (1985) (Abstract).
Lim, G.P., et al. “Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease”, Journal of Neuroscience, 20(15): 5709-5714 (2000).
Marjaux, E., et al. “γ-Secretase Inhibitors: Still in the Running a Alzheimer's Therapeutics”, Drug Discovery Today: Therapeutic Strategies, vol. 1, No. 1, (2004) p.
Morihara, T., et al. “Selective Inhibition of Aβ42 Production by NSAID R-Enantiomers”, Journal of Neurochemistry, 83, pp. 1009-1012 (2002).
Peretto, I., et al. “Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β-Amyloidi1-42Secretion”, J. Med. Chem. 48, pp. 5705-5720 (2005).
Saudek, C., et al. “A Preliminary Trial of the programmable Implantable Medication System for Insulin Delivery”, New England Journal of Medicine, vol. 321:574-579, No. 9 (1989) Abstract.
Shimizu, K., et al. “Binding of Delta, Jagged1, and Jagged1 to Notch1 Rapidly Induces Cleavage, Nuclear Translocation, and Hyperphosphorylation of Notch2”, Molecular and Cellular Biology, pp. 6913-6922 (2000).
Steiner, H., et al. “Uncovering γ-Secretase”, Current Alzheimer Research, 175-181 (2004).
Wang, R., et al. “The Profile of soluble amyloid βProtein in Cultured Cell Media”, Journal of Biological Chemistry, pp. 31894-31902 (1996).
Weggen, S., et al. “A subset of NSAIDs Lower Amyloidegenic Aβ42 Independently of Cyclooxygenase Activity”, Letters to Nature, vol. 414, * Nov. (2001) pp. 212-216.
Vassar, R., et al. “β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE”, Science, vol. 286, No. 5440, pp. 735-741 (1999).
Yan, R., et al “Membrane-Anchored Aspartyl Protease with Alzheimer's Disease β-Secretse Activity”, Letters to nature, vol. 42, pp. 533-537 (1999).
Yan, Q., et al. Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease, Journal of Neuroscience, 23(20): 7504-7509 (2003).
Xia, W., et al. “Presenilin 1 Regulates the Processing of β-Amyl lid Precursor Protein C-Terminal Fragments and the Generation of Amyloid β-Protein in Endoplasmic Reticulum and Golgi”, Biochemistry 37, pp. 16465-16471 (1998).
Janssen Pharmaceutica N.V.
Woodcock & Washburn LLP
Zucker Paul A
LandOfFree
Biphenyl carboxylic acids and derivatives thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biphenyl carboxylic acids and derivatives thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biphenyl carboxylic acids and derivatives thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2654696